Hematologic disorders associated with cancer: III. Coagulation disorders associated with neoplastic disease

  • Richard H. Steingart
Part of the Cancer Treatment and Research book series (CTAR, volume 30)


Hemorrhagic, thrombotic and embolic complications occur frequently in cancer patients. Diverse hemostatic alterations including impaired plasma coagulation, platelet abnormalities and vascular disorders account for these defects. Not only have these defects been ascribed to an effect of the malignancy, but in fact the entire sequence of cancer cell growth and metastasis is intimately entwined with the hemostatic system.


Factor VIII Acquire Immune Deficiency Syndrome Factor Xiii Clinical Bleeding Factor Xiii Deficiency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Billroth T. 1878. Lectures on surgical pathology and therapeutics (translated from the 8th edition). The New Sydenham Society.Google Scholar
  2. 2.
    Chew E, Wallace AC. 1976. Demonstration of fibrin in early stages of experimantal metastasis. Cancer Res 36:1904–1909.PubMedGoogle Scholar
  3. 3.
    Peterson HI. 1977. Fibrinolysis and antifibrinolytic drugs in the growth and spread of tumors. Cancer Treat Rep 1:213–217.CrossRefGoogle Scholar
  4. 4.
    Ross R, Voge A. 1978. The platelet derived growth factor: Review. Cell 14:203–210.PubMedCrossRefGoogle Scholar
  5. 5.
    Cliffton EE, Agostino VMD. 1964. Effect of inhibitors of fibrinolytic enzymes on development of pulmonary metastasis. J Natl Cancer Inst 33:753–763.PubMedGoogle Scholar
  6. 6.
    Zacharski LR, Henderson WG, Rickles FR et al. 1981. Effect of warfarin on survival in small cell carcinoma of the lung. JAMA 245:831–835.PubMedCrossRefGoogle Scholar
  7. 7.
    Rickles FR, Edwards RL. 1983. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 62:14–31.PubMedGoogle Scholar
  8. 8.
    Trousseau A. 1865. Phlegmasia alba dolens. Clinique Medicale de l’Hotel-dieu de Paris, London. New Sydenham Society 3:94.Google Scholar
  9. 9.
    Sack GH, Levin J, Bell W. 1977. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms. Clinical, pathologic and therapeutic features. Medicine 56:1–37.PubMedCrossRefGoogle Scholar
  10. 10.
    Bick RL. 1978. Alterations of hemostasis with malignancy. Sem Thromb. Hemost 5:1–26.Google Scholar
  11. 11.
    Ambrus JL, Ambrus CM, Mink IB et al. 1975. Causes of death in cancer patients. J Med 6:61–64.PubMedGoogle Scholar
  12. 12.
    Ambrus JL, Ambrus CM, Pickern J et al. 1975. Hematologic changes and thromboembolic complications in neoplastic disease and their relationship to metastasis. J Med 6:433–458.PubMedGoogle Scholar
  13. 13.
    Weiss RB, Toriney DC, Holland JF et al. 1981. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep 65:677–679.PubMedGoogle Scholar
  14. 14.
    Kasimis BS, Spiers AS. 1979. Thrombotic complications in patients with advanced prostatic cancer treated with chemotherapy. Lancet 1:159.PubMedCrossRefGoogle Scholar
  15. 15.
    Pineo GF, Brain MC, Galkes AS et al. 1974. Tumors, mucus production and hypercoagulability. Ann NY Acad Sci 230:262–270.PubMedCrossRefGoogle Scholar
  16. 16.
    Schafer AI. 1985. The hypercoagulable states. Ann. Intern Med 102:814–828.PubMedCrossRefGoogle Scholar
  17. 17.
    Gore JM, Appelbaum JS, Greene HL et al. 1982. Occult cancer in patients with acute pulmonary embolism. Ann Intern Med 96:556–560.PubMedCrossRefGoogle Scholar
  18. 18.
    Rohner RF, Prior JT, Sipple JH. 1966. Mucinous malignancies, venous thrombosis and terminal endocarditis with emboli. Cancer 19:1805–1812.Google Scholar
  19. 19.
    Sun NC, McAfee WM, Gibert JM et al. 1979. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Am J Clin Path 71:10–16.PubMedGoogle Scholar
  20. 20.
    Peusher FW, Cleton FJ, Armstrong L et al. 1980. Significance of plasma fibrinopeptide A (fpA) in patients with malignancy. J Lab Clin Med 96:5–14.Google Scholar
  21. 21.
    Rickles FR, Edwards RL, Baub C et al. 1983. Abnormalities of blood coagulation in patients with cancer. Cancer 51:301–307.PubMedCrossRefGoogle Scholar
  22. 22.
    Pineo GF, Regorezi F, Hatton MWC. 1973. The activation of coagulation by extracts of mucin: a possible pathway of intravascular coagulation accompanying adenocarcinomas. J Lab Clin Med 82:255–260.PubMedGoogle Scholar
  23. 23.
    Gralnick HR, Sultan C. 1975. Acute promyelocytic leukemia: Haemorrhagic manifestation and morphologic criteria. Br J Haematol 29:373–376.PubMedCrossRefGoogle Scholar
  24. 24.
    Drapkin RI, Gee TS, Dowling MD et al. 1978. Prophylactic heparin therapy in acute promyelocytic leukemia. Cancer 41:2484–2490.PubMedCrossRefGoogle Scholar
  25. 25.
    Goldsmith GH Jr. 1984. Hemostatic disorders associated with neoplasia. In: Disorders of Hemostasis. Ratnoff OD, Forbes CD, (eds). Grune & Stratton, Orlando, pp 351–363.Google Scholar
  26. 26.
    Cliffon EC, Grossi CE. 1955. Fibrinolytic activity of human tumors as measured by the fibrinplate method. Cancer 8:1146–1147.CrossRefGoogle Scholar
  27. 27.
    Davidson JF, McNicol GP, Frank GC. 1969. Plasminogen-activator producing tumor. Br. Med J 1:88–91.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Rachmilewitz EA. 1967. Defibrination syndrome followed by hypercoagulable state. Thromb Daith Haemorh 17:120–128.Google Scholar
  29. 29.
    Soong BC, Miller sp. 1970. Coagulation disorders in cancer III. Fibrinolysis and inhibitors. Cancer 25:867–874.PubMedCrossRefGoogle Scholar
  30. 30.
    Felten A, Straub RW, Frick PD. 1969. Dysfibrinogemia in a patient with primary hepatoma. First observation of an acquired abnormality in fibrin momomer aggregation. N. Engl J Med 280:405–409.CrossRefGoogle Scholar
  31. 31.
    Green G, Thomson JM, Dymock IW et al. 1976. Abnormal fibrin polymerization in liver disease. Br J Haematol 34:427–439.PubMedCrossRefGoogle Scholar
  32. 32.
    McGrath K, Koutts J. 1975. A case of Hageman factor deficiency with myeloid leukemia. Aust NE J Med 5:155–157.CrossRefGoogle Scholar
  33. 33.
    Rasche Dietrich M, Gaus W et al. 1974. Factor XIII-activity and fibin subunit structure in acute leukemia. Biomed 21:61–66.Google Scholar
  34. 34.
    Haseqawa DIC, Bennett AJ, Coccia PF et al. 1980. Factor V deficiency in Philadelphia-positive chronic myelogenous leukemia. Blood 56:585–595.Google Scholar
  35. 35.
    Phillips JP, O’Shea MJ. 1977. A new coagulation defect associated with a case of melanomatosis. J Clin Path 30:547–550.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Brody JI, Haidar MD, Rossman RE. 1979. A hemorrhagic syndrome in Waldenstrom’s macroglobinemia secondary to immunoadsorption of factor VIII. N Engl J Med 300:408–410.PubMedCrossRefGoogle Scholar
  37. 37.
    Wautier JL, Levy-Toledano S, Caen JP. 1976. Acquired von Willebrand’s syndrome and thrombopathy in a patient with chronic lymphocytic leukemia. Scand j Haematol 16:128–134.PubMedCrossRefGoogle Scholar
  38. 38.
    Joist JH, Cowein JF, Zimmerman TS. 1978. Acquired von Willebrand’s disease. N Engl J Med 298:988–991.PubMedCrossRefGoogle Scholar
  39. 39.
    Noronha PA, Hruby MA, Maurer HS. 1979. Acquired von Willebrand disease in a patient with Wilm’s tumor. J Peds 95:997–999.CrossRefGoogle Scholar
  40. 40.
    Shapiro SS, Hultin M. 1975. Acquired inhibitors to the blood coagulation factors. Sem Thromb Hemostat 1:336–351.Google Scholar
  41. 41.
    Furie B, Voo L, Kieth PW. 1981. Mechanism of factor X deficiency in sytemic amyloidosis. N Engl J Med 304:827–830.PubMedCrossRefGoogle Scholar
  42. 42.
    Greipp PR, Kyle RA, Bowie EW. 1979. Factor X deficiency in primary amyloidosis: resolution after splenectomy. N Engl J Med 301:1050–1051.PubMedCrossRefGoogle Scholar
  43. 43.
    Lackner H. 1973. Hemostatic abnormalities associated with dysproteinemias. Sem Hematol 10:125–133.Google Scholar
  44. 44.
    Palmer RN, Rick ME, Rick PD. 1984. Circulating heparin sulfate anticoagulant in a patient with a fatal bleeding disorder. N Engl J Med 310:1696–1699.PubMedCrossRefGoogle Scholar
  45. 45.
    Khoory MS, Nesheim ME, Bowie W. 1980. Circulating heparin sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder. J Clin Invest 65:666–673.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Perkins HA, McKenzie MR, Fudenberg HH. 1970. Hemostatic defects in dysproteinemias. Blood 35:695–707.PubMedGoogle Scholar
  47. 47.
    Goldsmith GH, Saito H, Muir WA. 1981. Labile anticoagulant in a patient with lymphoma. Am J Hematol 10:305–311.PubMedCrossRefGoogle Scholar
  48. 48.
    Scleider MA, Nachman RL, Jaffe EA et al. 1976. A clinical study of the lupus anticoagulant. Blood 48:499–509.Google Scholar
  49. 49.
    Yanq HC, Kuzur M. 1977. Procoagulant specificity of factor VIII inhibitor. Br J Haematol 37:429–433.CrossRefGoogle Scholar
  50. 50.
    Mueh JR, Herbst KD, Rapaport SI. 1980. Thrombosis in patients with lupus anticoagulants. Ann Intern Med 92:156–159.PubMedCrossRefGoogle Scholar
  51. 51.
    Criel A, Collen D, Masson PL. 1978. A case of IgM antibodies which inhibit the contact activation of blood coagulation. Thromb Res 12:883–892.PubMedCrossRefGoogle Scholar
  52. 52.
    Campbell EB, Sanal S, Mattson J et al. 1980. Factor VII inhibitor. Am J Med 68:962–964.PubMedCrossRefGoogle Scholar
  53. 53.
    Slickter SJ, Harker LA. 1974. Hemostasis in malignancy. Ann NY Acad Sci 230:252–261.CrossRefGoogle Scholar
  54. 54.
    Ingle JN, Tormey DC, Tan HK. 1978. The bone marrow examination in breast cancer. Cancer 41:67–674.CrossRefGoogle Scholar
  55. 55.
    Kim HD, Boggs DR. 1979. A syndrome resembling idiopathic thrombocytopenia purpura in 10 patients with diverse forms of cancer. Am J Med 67:371–276.PubMedCrossRefGoogle Scholar
  56. 56.
    Bellone JD, Kunnicki TH, Asrer RH. 1983. Immune thrombocytopenia associated with carcinoma. Ann Intern Med 99:470–472.PubMedCrossRefGoogle Scholar
  57. 57.
    Brook J, Konwaler BE. 1965. Thrombotic thrombcytopenic purpura. Association with metastatic gastric carcinoma and a possible autoimmune disorder. Calif Med 102:222–227.PubMedCentralPubMedGoogle Scholar
  58. 58.
    Friedman IA, Schwartzso, Leifhold SL. 1964. platelet function defects with bleeding. Arch Intern Med 113:177–185.CrossRefGoogle Scholar
  59. 59.
    Perkins HA, Mackenzie MR, Fudenberg HH. 1970. Hemostatic defects in dysproteinemias. Blood 35:695–707.PubMedGoogle Scholar
  60. 60.
    Pachter MR, Johnson SA, Neblett TR et al. 1959. Bleeding, platelets and macroglobulinemia. Am J Clin Pathol 31:467–482.PubMedGoogle Scholar
  61. 61.
    Saraya AK, Kasturi J, Kishan R. 1972. A study in hemostasis in macroglobulinemia. Acta Haematol 47:33–42.CrossRefGoogle Scholar
  62. 62.
    Penny R, Castaldi Pa, Whitsed HM. 1971. Inflammation and haemostasis in paraproteinemias. Br J Haematol 20:35–44.PubMedCrossRefGoogle Scholar
  63. 63.
    Lacker H. 1973. Hemostatic abnormalities associated with dysproteinemias. Sem. Hematol 10:125–133.Google Scholar
  64. 64.
    Brown CH, Bradshaw MW, Natelson EA et al. 1976. Defective platelet function following the administration of penicillin compounds. Blood 47:949–956.PubMedGoogle Scholar
  65. 65.
    Burgdorf W, Mukal K, Rosai J. 1979. Immunohistochemical identification of factor VIII in endothelial cells of normal skin and in cutaneous lesions of alleged vascular nature. Clin Res 27: 523A.Google Scholar
  66. 66.
    Lewis B, Abrams D, Ziegler J et al. 1983. Single agent or combination chemotherapy of Kaposi’s sarcoma in acquired immune deficiency sydrome. (Abstract) Pro Am Soc Clin Oncol 2:59.Google Scholar
  67. 67.
    Laubenstein LJ, Krigel RL, Hymes KB et al. 1983. Treatment of epidemic Kaposi’s sarcoma with vp-16–213 and a combination of doxorubicin, bleomycin and vinblastine. (Abstract) Pro Am Soc Clin Oncol 2:228.Google Scholar
  68. 68.
    Groopman JE, Gottlieb MS, Goodman J et al. 1984. Recombinant alpha-2 interferon therapy for Kaposi’s sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 100:671–676.PubMedCrossRefGoogle Scholar
  69. 69.
    Peters W. 1985. Personal communication.Google Scholar
  70. 70.
    Mintzer DM, Real FX, Jouino L. 1985. Treatment of kaposi’s sarcoma and thrombocytopenia with vincristine in patients with the acquired immunodeficiency syndrome. Ann Intern Med 102:200–202.PubMedCrossRefGoogle Scholar
  71. 71.
    Kitchens CS. 1984. The purpuric disorders. Sem Thromb Hemostat 10:173–189.CrossRefGoogle Scholar
  72. 72.
    Kyle RA, Bayrd ED. 1975. Amyloidosis. Review of 236 cases. Medicine (Baltimore) 54:271–299.CrossRefGoogle Scholar
  73. 73.
    Zlotnick A, Shahin W, Rachmilewltz EA. 1969. Studies in cryofibrinogenemia. Acta Haematol 42:8–17.PubMedCrossRefGoogle Scholar
  74. 74.
    Prockop DJ, Kiuirikko KI. 1967. Hydroxyproline and the metabolism of collagen. In: Biology of collagen vol 2 of treatise on collagenld. Gould S (ed).Academic Press, London, p 230.Google Scholar
  75. 75.
    Ramsay NIC, Coccia PF, Kriuit W et al. 1977. The effect of L-asparaginase on plasma coagulation factors in acute lymphoblastic leukemia. Cancer 40:1398–1401.PubMedCrossRefGoogle Scholar
  76. 76.
    Monto RW, Talley RW, Caldwell MJ. 1969. Observations on the mechanisms of hemorrhagic toxicity in mithramycin therapy. Cancer Res 29:697–703.PubMedGoogle Scholar
  77. 77.
    Ahr DJ, Scialla SJ, Kimball DB. 1978. Acquired platelet dysfunction following mithramycin therapy. Cancer 41:448–454.PubMedCrossRefGoogle Scholar
  78. 78.
    Bick RL, Fekete WF, Wilson WL. 1976. Adriamycin and fibrinolysis. Thromb. Res 8:467–475.PubMedCrossRefGoogle Scholar
  79. 79.
    Bick RL, Feket L, Murano G. 1976. Daunamycin and fibrinolysis. Thromb Res 9:201–203.PubMedCrossRefGoogle Scholar
  80. 80.
    Klener P, Kubisz P, Suranova J. 1977. Influence of cytotoxic drugs on platelet functions and coagulation. Thromb Haemostat 37:53–61.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1986

Authors and Affiliations

  • Richard H. Steingart

There are no affiliations available

Personalised recommendations